Psychiatry news topic
Treatment updates
Every update we have published on treatment updates, newest first. Each report names the primary source so you can check it yourself.
October 13, 2026
SPRAVATO® without an oral antidepressant: what changed
The 2025 FDA label expansion allows SPRAVATO® alone for adults with treatment-resistant depression. Supervised treatment and safety requirements still apply.
Primary source: FDA supplemental approval letter
October 13, 2026
Cobenfy for schizophrenia: a different approach, with limits
Cobenfy’s 2024 approval added a muscarinic-based option for adults with schizophrenia. Here is what the trials and current safety labeling can—and cannot—tell patients.
Primary source: FDA Drug Trials Snapshot: Cobenfy